GLP-1 agonists, DPP-4 inhibitors off the hook, for now
This article was originally published in Scrip
Executive Summary
There is currently no evidence that GLP-1 agonists and DPP-4 inhibitors lead to a heightened risk of pancreatic adverse events, says the European Medicines Agency's Committee for Medicinal Products for Human Use. The CHMP has recently concluded a review of the products and found that a study that sparked concerns was limited in several ways.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.